Estradiol Enanthate
Long-acting injectable estradiol ester, historically paired with dihydroxyprogesterone acetophenide in the monthly injectable contraceptive Perlutal/Topasel. Provides extended estradiol release for HRT and feminization.
01 Overview
Estradiol enanthate is a slow-release ester of 17-beta-estradiol. Its best-documented use is as the estrogen component of once-monthly combined injectable contraceptives popular in Latin America. It is also used in feminizing hormone therapy where a long dosing interval is desired.
Because data in transfeminine care come largely from smaller series and contraceptive literature, dosing is individualised and monitored by serum estradiol.
02 Mechanism
Enanthate ester hydrolyses to 17-beta-estradiol, activating estrogen receptors and suppressing the HPG axis.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Feminizing HRT | 3–10 mg/wk | IM | Given every 1-2 weeks; titrate to serum estradiol. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| FeminizationBreast development and fat redistribution as with other estradiol esters. | Observational | ||
| Long dosing intervalExtended release allows less frequent injection. | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Venous thromboembolismClass estrogen clotting risk. | Severe | Uncommon | Clinical | |
| Estradiol overshootLong ester makes correcting high levels slow. | Moderate | Common with large depots | Observational |